Comparative Evaluate the Efficacy to Acute and Chronic Bronchitis

Double-blind, A Multicenter, Randomized, Placebo-controlled, Parallel, Phase 2 Study to Comparative Evaluate the Efficacy of N02RS1 600mg/Day, 12,00mg/Day in Korean Patients With Acute and Chronic Bronchitis

The Purpose of A Multicenter, Randomized, Double-blind, Placebo-controlled to Evaluate the Efficacy, Safety and Pharmacokinetics of N02RS1 600mg and 1,200mg per day in Patients With acute and acute exacerbation of chronic bronchitis for 7 days.

Inclusion Criteria:

• Patients over 18, under 75 years of age
• Patients Acute and Chronic Bronchitis

Exclusion Criteria:

• Patients who have gotten a glucocorticoids treatment within 4 weeks.
• Patients who need treatments of antibiotic and acute bronchitis infection.
• Patients who have gotten teatments of antibiotic,bronchodilator,painkiller and secretagog within 7 days.
• Bronchial asthma patient.
• Patients who have an indication of bleeding.
• Patients who have a serious heart and renal disease or liver ailment or immunosuppressive response.
• Patients who have history of over 3 phage of Chronic obstructiv lung disease
• Bronchiectasis patients.